8 LIONS ENTERTAINMENT AND LUPUS FILMS GO GLOBAL WITH ‘THE HIVE’ - UK Screen Alliance

Response rates with litifilimab, a monoclonal antibody targeting blood dendritic cell antigen 2 (BDCA2), continued to rise through week 52 in patients with cutaneous lupus erythematosus (CLE) refractory or intolerant to antimalarials, according to Victoria P. Werth, MD, professor of dermatology and medicine at the University of Pennsylvania, and François Chasset, MD, PhD, professor of dermatology at Sorbonne Université and Hôpital Tenon in Paris. The 2 discussed the phase 2 AMETHYST Part A data in an HCPLive special report from the European Academy of Dermatology and Venereology (EADV) Congress 2026 in Vienna, Austria (September 30–October 3). The findings come from a Biogen-sponsored congress abstract that has not been peer-reviewed, and both speakers are authors on it.1 AMETHYST Part A (NCT05531565) randomized 93 adults to subcutaneous litifilimab (n = 59) or placebo (n = 34) every 4 weeks through week 24, after which all participants received litifilimab through week 52.1 Chasset noted the cohort was 74% women and 33% non-white.

CNN legend Christiane Amanpour, the network’s chief international anchor, said Monday that she will sign off from CNN next June.